NASDAQ:MRTX

Mirati Therapeutics (MRTX) Price Target & Analyst Ratings

$37.00

+9.20 (+33.09%)

(As of 08/9/2023 ET)

Compare

Today's Range: $33.45
▼
$37.55
50-Day Range: $27.80
▼
$40.50
52-Week Range: $27.30
▼
$101.30

Volume: 7.53 million shs
Average Volume: 1.13 million shs
Market Capitalization: $2.15 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $63.15

Mirati Therapeutics Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 13 Analyst Ratings

Consensus Analyst Price Target

$59.85
61.75% Upside

High Prediction	$100.00
Average Prediction	$59.85
Low Prediction	$31.00

Type	Current 8/10/22 to 8/10/23	1 Month Ago 7/11/22 to 7/11/23	3 Months Ago 5/12/22 to 5/12/23	1 Year Ago 8/10/21 to 8/10/22
Consensus Rating	Hold	Hold	Hold	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	7 Buy rating(s)	5 Buy rating(s)	6 Buy rating(s)	10 Buy rating(s)
Hold	5 Hold rating(s)	6 Hold rating(s)	7 Hold rating(s)	3 Hold rating(s)
Sell	1 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$59.85	$68.38	$81.13	$129.54
Predicted Upside	61.75% Upside	31.05% Upside	53.57% Upside	44.57% Upside

Get Mirati Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for MRTX and its competitors with MarketBeat's FREE daily newsletter.

MRTX Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MRTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Mirati Therapeutics Stock vs. The Competition

Type	Mirati Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.46	2.65	2.48
Consensus Rating	Hold	Moderate Buy	Hold
Predicted Upside	70.48% Upside	5,105.36% Upside	636.80% Upside
News Sentiment Rating	Positive News	Neutral News	Neutral News

Historical Target Prices and Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/9/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$45.00	+21.62%
8/9/2023	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$40.00 ➝ $31.00	-11.05%
8/9/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$77.00 ➝ $83.00	+132.69%
8/9/2023	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$45.00	+61.87%
8/9/2023	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$56.00 ➝ $62.00	+123.02%
7/27/2023	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Underperform
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
7/24/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy	$104.00 ➝ $60.00	+93.61%
7/24/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$54.00 ➝ $46.00	+46.92%
7/24/2023	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight	$75.00 ➝ $71.00	+126.76%
7/14/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight	$51.00 ➝ $42.00	+13.91%
5/11/2023	VNET Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
5/11/2023	22nd Century Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Reiterates
12/14/2022	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$85.00 ➝ $75.00	+78.70%
12/14/2022	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold
12/9/2022	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$121.00 ➝ $53.00	+20.87%
12/8/2022	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Neutral	$94.00 ➝ $65.00	+31.07%
9/13/2022	Jonestrading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Soumit Roy Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$100.00	+21.77%

(Data available from 8/10/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

MRTX Price Target - Frequently Asked Questions

What is Mirati Therapeutics's consensus rating and price target?: According to the issued ratings of 13 analysts in the last year, the consensus rating for Mirati Therapeutics stock is Hold based on the current 1 sell rating, 5 hold ratings and 7 buy ratings for MRTX. The average twelve-month price prediction for Mirati Therapeutics is $59.85 with a high price target of $100.00 and a low price target of $31.00. Learn more on MRTX's analyst rating history.
Do Wall Street analysts like Mirati Therapeutics more than its competitors?: Analysts like Mirati Therapeutics less than other Medical companies. The consensus rating for Mirati Therapeutics is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how MRTX compares to other companies.
Is Mirati Therapeutics being upgraded by Wall Street analysts?: Over the previous 90 days, Mirati Therapeutics's stock had 2 upgrades by analysts.

Does Mirati Therapeutics's stock price have much upside?: According to analysts, Mirati Therapeutics's stock has a predicted upside of 46.67% based on their 12-month price targets.
What analysts cover Mirati Therapeutics?: Mirati Therapeutics has been rated by B. Riley, Bank of America, Barclays, BMO Capital Markets, Guggenheim, Morgan Stanley, Oppenheimer, Piper Sandler, Scotiabank, and Stifel Nicolaus in the past 90 days.

Stock Ratings Reports and Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

This page (NASDAQ:MRTX) was last updated on 8/10/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial